Mineralys Therapeutics, Inc. (MLYS) Research

Mineralys Therapeutics, Inc. (MLYS) is a pioneering biopharmaceutical company currently advancing through clinical trials. Its primary focus lies in creating innovative treatments for high blood pressure and its related cardiovascular complications. The company's leading investigational drug is lorundrostat. This exclusive, orally administered compound functions as a highly targeted aldosterone synthase inhibitor, specifically being developed to address difficult-to-treat cases of uncontrolled or resistant hypertension. Established in 2019, Mineralys Therapeutics operates from its headquarters in Radnor, Pennsylvania.

Market snapshot

Symbol
MLYS
Price
$24.63
Day change
-1.99%
Market cap
$1.6B
P/E ratio
-13.44x
52-week range
12.59-47.65
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$46.00

Recent news

  • Mineralys' pill cuts blood pressure in kidney disease patients

    Mineralys Therapeutics' experimental drug significantly reduced blood pressure in patients with chronic kidney disease, according to new data presented at a major ​European medical conference on Saturday.

Peer companies

  • Adaptive Biotechnologies Corporation (ADPT)
  • Agios Pharmaceuticals, Inc. (AGIO)
  • Apellis Pharmaceuticals, Inc. (APLS)
  • Beam Therapeutics Inc. (BEAM)
  • Cidara Therapeutics, Inc. (CDTX)
  • Catalyst Pharmaceuticals, Inc. (CPRX)
  • IDEAYA Biosciences, Inc. (IDYA)
  • Recursion Pharmaceuticals, Inc. (RXRX)

Recent insider activity

  • Rodman David Malcom — M-Exempt (3542 shares) on 2026-06-15
  • Rodman David Malcom — M-Exempt (4167 shares) on 2026-06-17
  • Rodman David Malcom — M-Exempt (3542 shares) on 2026-06-15
  • Rodman David Malcom — M-Exempt (417 shares) on 2026-06-17
  • Rodman David Malcom — M-Exempt (4167 shares) on 2026-06-17

Open Mineralys Therapeutics, Inc. (MLYS) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.